Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

Fig. 3

Median CRP levels by time period, categorized by CDAI remission at months 6 and 12. Plots show median CRP levels by time period for a patients who achieved CDAI remission (≤ 2.8) at month 6, b patients who did not achieve CDAI remission (> 2.8) at month 6, c patients who achieved CDAI remission (≤ 2.8) at month 12, and d patients who did not achieve CDAI remission (> 2.8) at month 12. Error bars represent the interquartile range (Q1‒Q3). ADA, adalimumab, CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; MTX, methotrexate; Q1, 25th percentile; Q3, 75th percentile

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us